Skip to content

Cogent Biosciences

US · COGT #2052 by market cap Listed 2016
26.72 -1.03 -3.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:53

Recent news

  • Rating change
    J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)
    TipRanks · 2026/3/14
  • Rating change
    Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52
    Market Newswire · 2026/5/7
  • H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $56
    Market Newswire · 2026/11/9
  • Rating change
    Needham Maintains Cogent Biosciences(COGT.US) With Hold Rating
    Market Newswire · 2026/8/11
  • J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $61
    Market Newswire · 2026/11/13
  • Rating change
    Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $52
    Market Newswire · 2026/8/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR)
    TipRanks · 2026/6/1
  • Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/9/17
  • Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/11/6
  • Rating change
    LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/9/16
  • Rating change
    J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $62
    Market Newswire · 2026/9/9
  • UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/10/14
  • Rating change
    J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $64
    Market Newswire · 2026/3/14
  • Rating change
    A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $45 to $55
    Market Newswire · 2026/5/6
  • Rating change
    J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating
    Market Newswire · 2026/6/1
  • Rating change
    Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/4/2
  • Rating change
    H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/9/17
  • Rating change
    H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52
    Market Newswire · 2026/4/2
  • Rating change
    Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $55
    Market Newswire · 2026/8/17
  • Rating change
    Jefferies Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $55
    Market Newswire · 2026/3/16
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT)
    TipRanks · 2026/3/2
  • Rating change
    Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/2/19
  • Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/10/27
  • Rating change
    Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/6/15
  • Rating change
    UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/6/1

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:53:23 · For reference only, not investment advice and not tailored to your situation.

Cogent Biosciences discussion 0 comments

Add a comment